A Five Part Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Single and Repeat Oral Doses of FDL176 in Healthy and Cystic Fibrosis (CF) Participants

Next Previous
Trial Profile

A Five Part Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Single and Repeat Oral Doses of FDL176 in Healthy and Cystic Fibrosis (CF) Participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs FDL 176 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 5 Mar 2018 to 29 Jun 2018.
    • 11 Apr 2018 Planned primary completion date changed from 5 Mar 2018 to 29 Jun 2018.
    • 17 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top